Olmesartan Dialyzability in Hemodialysis Patients

Pharmacokinetic Properties and Clinical Evidence

• Unlike some beta-blockers, angiotensin receptor blockers like olmesartan behave differently due to their high protein binding, making them non-dialyzable in patients with kidney impairment, as noted by the American Heart Association 1, 2

Renal Impairment Considerations

• No specific facts are available with a citation id in this section.

Important Clinical Pitfalls

• No additional unique facts are available with a citation id in this section.